© 2004 BMJ Publishing Group Ltd & British Thoracic Society
LUNG ALERT
The use of opioids for palliative care in refractory dyspnoea
Specialist Registrar in Respiratory Medicine, Chest Clinic C, Foresterhill, Aberdeen Royal Infirmary, Aberdeen, UK; graeme_currie@yahoo.com
| The first 150 words of the full text of this article appear below. |
Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained releases morphine for the management of refractory dyspnoea. BMJ 2003;327:5236
Dyspnoea is a disabling and distressing problem for many patients and carers. Clinicians are often reluctant to prescribe opioids for such patients because of concerns of adverse effectsparticularly respiratory depression and sedationand paucity of evidence of clinical benefit.
Abernethy and colleagues conducted a small (n = 48) double blind, placebo controlled, crossover study. Patients, most of whom had chronic obstructive pulmonary disease (n = 42), were randomised to receive 20 mg/day sustained release morphine or identical placebo. No washout period between the 4 day treatment periods was employed, although the authors acknowledge some carryover effect in patients receiving morphine first in sequence. Patients reported significantly less dyspnoea according to a visual analogue scale and had less sleep disturbance when using
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
